A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease

NCT00818662 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

390

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer´s Disease

Interventions

BIOLOGICAL: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg
BIOLOGICAL: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg
BIOLOGICAL: Placebo solution: Human Albumin 0.25% - 4 mL/kg
BIOLOGICAL: Placebo solution: Human Albumin 0.25% - 2 mL/kg

Sponsor

Baxalta now part of Shire

Collaborators

[object Object]